StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11+0.00 (0.00%)

Close on Nov 18, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Rocket Pharmaceuticals's cash was $283.70M at Jun 30, 2026. For fiscal 2025 it was $188.90M, down 49.3% from the year before. Over ten years it grew 5.4% a year on average. The highest annual figure on record is $482.70M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$188.90M-49.3%
FY2024Dec 31, 2024$372.30M-8.6%
FY2023Dec 31, 2023$407.50M+13.9%
FY2022Dec 31, 2022$357.73M-8.0%
FY2021Dec 31, 2021$388.70M-19.5%
FY2020Dec 31, 2020$482.70M+58.7%
FY2019Dec 31, 2019$304.10M+42.7%
FY2018Dec 31, 2018$213.13M+113.1%
FY2017Dec 31, 2017$100.01M-20.9%
FY2016Dec 31, 2016$126.47M+13.7%
FY2015Dec 31, 2015$111.28M+2975.7%
FY2014Dec 31, 2014$3.62M-71.7%
FY2013Dec 31, 2013$12.79M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$283.70M+4.5%
Q1 FY2026Mar 31, 2026$144.40M-54.6%
Q4 FY2025Dec 31, 2025$188.90M-49.3%
Q3 FY2025Sep 30, 2025$222.80M-5.5%
Q2 FY2025Jun 30, 2025$271.50M-2.6%
Q1 FY2025Mar 31, 2025$318.20M-3.7%
Q4 FY2024Dec 31, 2024$372.30M-8.6%
Q3 FY2024Sep 30, 2024$235.70M-46.1%
Q2 FY2024Jun 30, 2024$278.80M-9.2%
Q1 FY2024Mar 31, 2024$330.30M-8.3%
Q4 FY2023Dec 31, 2023$407.50M+13.9%
Q3 FY2023Sep 30, 2023$437.20M+42.6%
Q2 FY2023Jun 30, 2023$307.00M-4.5%
Q1 FY2023Mar 31, 2023$360.00M+3.9%
Q4 FY2022Dec 31, 2022$357.73M-8.0%
Q3 FY2022Sep 30, 2022$306.50M-27.3%
Q2 FY2022Jun 30, 2022$321.40M-24.7%
Q1 FY2022Mar 31, 2022$346.60M-25.7%
Q4 FY2021Dec 31, 2021$388.70M-19.5%
Q3 FY2021Sep 30, 2021$421.50M+84.3%
Q2 FY2021Jun 30, 2021$426.80M+70.9%
Q1 FY2021Mar 31, 2021$466.40M+69.0%
Q4 FY2020Dec 31, 2020$482.70M+58.7%
Q3 FY2020Sep 30, 2020$228.70M-4.9%
Q2 FY2020Jun 30, 2020$249.80M-3.1%
Q1 FY2020Mar 31, 2020$275.90M+40.3%
Q4 FY2019Dec 31, 2019$304.10M+42.7%
Q3 FY2019Sep 30, 2019$240.60M+50.9%
Q2 FY2019Jun 30, 2019$257.80M+50.4%
Q1 FY2019Mar 31, 2019$196.60M+7.6%
Q4 FY2018Dec 31, 2018$213.13M+113.1%
Q3 FY2018Sep 30, 2018$159.48M+54.6%
Q2 FY2018Jun 30, 2018$171.47M+57.7%
Q1 FY2018Mar 31, 2018$182.70M+59.3%
Q4 FY2017Dec 31, 2017$100.01M-20.9%
Q3 FY2017Sep 30, 2017$103.13M-25.0%
Q2 FY2017Jun 30, 2017$108.75M–
Q1 FY2017Mar 31, 2017$114.71M–
Q4 FY2016Dec 31, 2016$126.47M–
Q3 FY2016Sep 30, 2016$137.58M–

More Rocket Pharmaceuticals figures

See a number that looks wrong?